The people included in the study suffered from headaches, tremors, muscle spasms, insomnia, sleepiness, vertigo, and difficulty in concentration.<\/h5>\n\n\n\n![\"Nearly](\"https:\/\/www.theepochtimes.com\/_next\/image?url=https%3A%2F%2Fimg.theepochtimes.com%2Fassets%2Fuploads%2F2023%2F09%2F15%2Fid5492450-GettyImages-1232432440.jpg&w=1200&q=75\")
Empty COVID-19 vaccine vials at a vaccination center in Rosenheim, Germany, on April 20, 2021. (Christof Stache\/AFP via Getty Images)<\/figcaption><\/figure>\n\n\n\nBy Naveen Athrappully<\/p>\n\n\n\n
Almost a third of individuals who received a COVID-19 vaccine suffered from neurological complications including tremors, insomnia, and muscle spasms, according to a recent study published in the journal Vaccines<\/a>.<\/p>\n\n\n\nThe study analyzed 19,096 people who received COVID-19 vaccines in Italy in July 2021, out of which 15,368 had taken the Pfizer vaccine, 2,077 had taken the Moderna version, and 1,651 took the AstraZeneca version.<\/p>\n\n\n\n
While both Pfizer and Moderna are mRNA vaccines, AstraZeneca, being an adenovirus vaccine, uses a different mechanism to trigger the immune response.<\/p>\n\n\n\n
The study found that about 31.2 percent of vaccinated individuals developed post-vaccination neurological complications, particularly among those injected with the AstraZeneca jab. Different vaccines had a different \u201cneurological risk profile.\u201d<\/p>\n\n\n\n
The neurological risk profile of the AstraZeneca vaccine included headaches, tremors, muscle spasms, insomnia, and tinnitus, while the risk profile of the Moderna vaccine included sleepiness, vertigo, diplopia (double vision), paresthesia (a feeling of numbness or itching on the skin), taste and smell alterations, and dysphonia (hoarseness or loss of normal voice).<\/p>\n\n\n\n
As to Pfizer vaccines, researchers found \u201can increased risk\u201d of cognitive fog or difficulty in concentration.<\/p>\n\n\n\n
AstraZeneca Risks<\/h2>\n\n\n\n
More than 53 percent of individuals who took an AstraZeneca shot suffered from headaches, which usually lasted for one day. Over 13 percent developed tremors, which typically reverted after a day as well.<\/p>\n\n\n\n
Insomnia was reported among 5.8 percent of AstraZeneca recipients. However, the study notes that researchers were unsure whether the individuals actually developed insomnia or had a \u201cmisperception of their sleep quality due to vaccination stress.\u201d<\/p>\n\n\n\n
Tinnitus was reported by 2.7 percent of the people who took AstraZeneca shots. Tinnitus is a condition in which an individual hears ringing or other noises which are not caused by an external sound.<\/p>\n\n\n\n
All these health complications had a higher risk of occurring after taking the first dose of the vaccine.<\/p>\n\n\n\n
The study speculated that complications related to the AstraZeneca vaccine are attributable to two factors. \u201cFirstly, the nature of the vaccine, which is a modified adenovirus vector that results in significant and persistent systemic immune activation; secondly, individual vulnerability related to a predisposing biology.\u201d<\/p>\n\n\n\n
Moderna and Pfizer Risks<\/h2>\n\n\n\n
Sleepiness was found in 39.7 percent of those who took Moderna jabs, with the condition usually lasting for a week. It suggested that there \u201ccould be a strict relationship between the development of sleepiness and immune responses to vaccine\/infection.\u201d<\/p>\n\n\n\n
The study cited a \u201cfascinating hypothesis\u201d which suggests that influenza vaccines may lead to \u201cthe selective immune-mediated destruction of orexin-producing neurons, which is T-cell-mediated neuronal damage, thus triggering narcolepsy.\u201d<\/p>\n\n\n\n![\"](\"https:\/\/www.theepochtimes.com\/_next\/image?url=https%3A%2F%2Fimg.theepochtimes.com%2Fassets%2Fuploads%2F2023%2F09%2F15%2Fid5492418-GettyImages-1231208047-1200x800.jpg&w=1200&q=75\")
A medical assistant holds a tray of syringes filled with doses of Moderna COVID-19 vaccine at a vaccination site in Los Angeles on Feb. 16, 2021. (Apu Gomes\/AFP via Getty Images)<\/figcaption><\/figure>\n\n\n\nNarcolepsy is a condition in which the brain is unable to control the ability to sleep or stay awake.<\/p>\n\n\n\n
\u201cConsidering that the same can occur for COVID-19 vaccines, future investigations monitoring the new-onset hypersomnia findings in vulnerable individuals are urgently needed.\u201d<\/p>\n\n\n\n
Hypersomnia is the inability to stay awake and alert during the daytime, even though the person may have had plenty of sleep during the night.<\/p>\n\n\n\n
About 15.9 percent of people who received Moderna shots had vertigo, a sensation which makes the individual feel that they or their surrounding environment is moving or spinning. It typically lasted for a day.<\/p>\n\n\n\n
Paresthesia\u2014a feeling of numbness or itching on the skin for no apparent reason\u2014was reported<\/a> in 14.5 percent of Moderna vaccine recipients, which went away after a day.<\/p>\n\n\n\nAmong the people who received a Moderna jab, 2.7 percent reported diplopia, also known as double vision, which also lasted for about a day. \u201cSymptomatic people showed an increased risk to develop diplopia after the second dose, as if a reactivation of the immune response was necessary to trigger diplopia.\u201d<\/p>\n\n\n\n
Meanwhile, about 6.4 percent of Pfizer vaccine recipients reported suffering from cognitive fog, with the condition usually reversing in a week.<\/p>\n\n\n\n
\u201cBrain fog is a type of cognitive impairment that presents as a \u2018foggy brain state\u2019, including a lack of intellectual clarity, difficulty with concentration, mental fatigue and anxiety,\u201d the study said.<\/p>\n\n\n\n
\u201cHypotheses including systemic inflammation crossing the blood\u2013brain barrier, neuroinflammation after viral infection leads and microglial activation are emerging as explanations of this phenomenon in COVID-19 patients. An alternative speculation is that symptomatic people may have a subclinical cognitive dysfunction before vaccination, and that vaccination is a trigger.\u201d<\/p>\n\n\n\n
Females Highly Affected<\/h2>\n\n\n\n
The study found that females faced an \u201cincreased risk of developing neurological complications\u201d following COVID-19 vaccination. \u201cOur findings are in line with those of a recent study that revealed that several factors, including the female sex, were associated with greater odds of adverse effects,\u201d it said.<\/p>\n\n\n\n
The researchers suggested that greater female susceptibility to the vaccines\u2019 neurological complications may be due to \u201cgenetic and hormonal factors.\u201d<\/p>\n\n\n\n
Females have two X chromosomes while males have one X chromosome and one Y chromosome. As the X chromosome \u201ccontains the most prominent immune-related genes in the human genome,\u201d it can also cause \u201cstronger inflammatory immune responses,\u201d the study said.<\/p>\n\n\n\n![\"](\"https:\/\/www.theepochtimes.com\/_next\/image?url=https%3A%2F%2Fimg.theepochtimes.com%2Fassets%2Fuploads%2F2023%2F05%2F14%2Fid5264817-vaccine-e1684105319169-1200x738.jpg&w=1200&q=75\")
A COVID-19 vaccination hub at Central Falls High School in Central Falls, R.I., on Feb. 13, 2021. (Joseph Prezioso\/AFP via Getty Images)<\/figcaption><\/figure>\n\n\n\nMoreover, a primary female sex steroid called estradiol triggers a specific immunity process to produce \u201cantibodies against infections.\u201d<\/p>\n\n\n\n
The study also raised concerns about comorbidities. In medical parlance, comorbidity describes the existence of more than one disease or condition in a body at the same time, which may or may not interact with one another.<\/p>\n\n\n\n
\u201cThe evidence that immune system dysfunctions (allergies\/immunodeficiency disorders) are frequently reported in our symptomatic group is more than a chance occurrence,\u201d researchers said.<\/p>\n\n\n\n
Comorbidities were present in 47.6 percent of the AstraZeneca vaccine recipients, 38.8 percent of those who took Moderna jabs, and 41.5 percent of individuals who received Pfizer shots, the study said.<\/p>\n\n\n\n
In the AstraZeneca group, both allergies and non-neurological diseases were reported. \u201cA history of antitumoral and anticoagulant drugs was more frequent in this population,\u201d the study said.<\/p>\n\n\n\n
Among Moderna and Pfizer recipients, allergies were \u201cmore frequently\u201d observed. While some people who took Moderna had a prior history of neurological diseases and transfusions as well as previous COVID-19 infection, those who received Pfizer vaccines had a history of immunodeficiency disorders.<\/p>\n\n\n\n
Even though the study detailed neurological complications arising from COVID-19 vaccination, it admitted to certain limitations.<\/p>\n\n\n\n
\u201cFirstly, our results should be interpreted with caution because of a possible overestimation of neurological events resulting from the self-reported symptoms,\u201d it said.<\/p>\n\n\n\n
\u201cSecondly, we evaluated the risks associated with the first and second doses of the vaccine; however, the data concerning the second dose were limited, thus representing a potential bias in the study.\u201d<\/p>\n\n\n\n
While admitting its limitations, the study concluded that \u201cclinicians should be aware that several neurological complications may commonly occur after COVID-19 vaccines.\u201d<\/p>\n\n\n\n
\u201cCaution should be used when administering COVID-19 vaccines to vulnerable people, such as to those who suffer from allergies,\u201d the study stated. \u201cWe strongly believe that our findings are relevant for public health regarding the safety of vaccines in a large cohort.\u201d<\/p>\n\n\n\n
The Epoch Times reached out to Moderna, Pfizer, and AstraZeneca for comment.<\/p>\n\n\n\n
Additional Neurological Findings<\/h2>\n\n\n\n
Cardiologist Dr. Peter McCullough wrote about the study<\/a> discussing neurological effects following COVID shots in an article on Substack.<\/p>\n\n\n\n\u201cA shocking 31.2 percent of respondents to this large dataset sustained neurologic injury after two injections with verified data in health registries,\u201d he wrote. \u201cMost of the risk estimates indicate the safety profile is unacceptable. It is alarming that all neurological societies to date still recommend COVID-19 vaccines and none have issued safety warnings on the products.\u201d<\/p>\n\n\n\n
Dr. McCullough explained that an excess risk of 20 percent or greater is considered “clinically important.”<\/p>\n\n\n\n
Multiple other studies have found evidence of COVID-19 vaccines being linked to neurological complications. Back in October 2021, a study<\/a> published in the Neurological Sciences journal stated that the \u201cmost devastating neurological post-vaccination complication is cerebral venous sinus thrombosis (CVST).\u201d<\/p>\n\n\n\nCVST occurs when a blood clot develops in the venous sinuses of the brain. This blocks the blood from draining out of the brain, eventually resulting in the blood leaking into brain tissues and forming a hemorrhage, according to Johns Hopkins Medicine.<\/p>\n\n\n\n
The study found that CVST was \u201cfrequently reported in females of childbearing age,\u201d generally among those who took an adenovector vaccine. Individuals who received mRNA vaccination were reported to have Bell\u2019s palsy, in which facial muscles weaken or enter into paralysis.<\/p>\n\n\n\n
A November 2022 study in Current Neurology and Neuroscience Reports<\/a> made similar findings, stating that there is \u201ca greater than expected occurrence of severe neurological adverse events.”<\/p>\n\n\n\n
By Naveen Athrappully<\/p>\n\n\n\n
Almost a third of individuals who received a COVID-19 vaccine suffered from neurological complications including tremors, insomnia, and muscle spasms, according to a recent study published in the journal Vaccines<\/a>.<\/p>\n\n\n\n The study analyzed 19,096 people who received COVID-19 vaccines in Italy in July 2021, out of which 15,368 had taken the Pfizer vaccine, 2,077 had taken the Moderna version, and 1,651 took the AstraZeneca version.<\/p>\n\n\n\n While both Pfizer and Moderna are mRNA vaccines, AstraZeneca, being an adenovirus vaccine, uses a different mechanism to trigger the immune response.<\/p>\n\n\n\n The study found that about 31.2 percent of vaccinated individuals developed post-vaccination neurological complications, particularly among those injected with the AstraZeneca jab. Different vaccines had a different \u201cneurological risk profile.\u201d<\/p>\n\n\n\n The neurological risk profile of the AstraZeneca vaccine included headaches, tremors, muscle spasms, insomnia, and tinnitus, while the risk profile of the Moderna vaccine included sleepiness, vertigo, diplopia (double vision), paresthesia (a feeling of numbness or itching on the skin), taste and smell alterations, and dysphonia (hoarseness or loss of normal voice).<\/p>\n\n\n\n As to Pfizer vaccines, researchers found \u201can increased risk\u201d of cognitive fog or difficulty in concentration.<\/p>\n\n\n\n More than 53 percent of individuals who took an AstraZeneca shot suffered from headaches, which usually lasted for one day. Over 13 percent developed tremors, which typically reverted after a day as well.<\/p>\n\n\n\n Insomnia was reported among 5.8 percent of AstraZeneca recipients. However, the study notes that researchers were unsure whether the individuals actually developed insomnia or had a \u201cmisperception of their sleep quality due to vaccination stress.\u201d<\/p>\n\n\n\n Tinnitus was reported by 2.7 percent of the people who took AstraZeneca shots. Tinnitus is a condition in which an individual hears ringing or other noises which are not caused by an external sound.<\/p>\n\n\n\n All these health complications had a higher risk of occurring after taking the first dose of the vaccine.<\/p>\n\n\n\n The study speculated that complications related to the AstraZeneca vaccine are attributable to two factors. \u201cFirstly, the nature of the vaccine, which is a modified adenovirus vector that results in significant and persistent systemic immune activation; secondly, individual vulnerability related to a predisposing biology.\u201d<\/p>\n\n\n\n Sleepiness was found in 39.7 percent of those who took Moderna jabs, with the condition usually lasting for a week. It suggested that there \u201ccould be a strict relationship between the development of sleepiness and immune responses to vaccine\/infection.\u201d<\/p>\n\n\n\n The study cited a \u201cfascinating hypothesis\u201d which suggests that influenza vaccines may lead to \u201cthe selective immune-mediated destruction of orexin-producing neurons, which is T-cell-mediated neuronal damage, thus triggering narcolepsy.\u201d<\/p>\n\n\n\n Narcolepsy is a condition in which the brain is unable to control the ability to sleep or stay awake.<\/p>\n\n\n\n \u201cConsidering that the same can occur for COVID-19 vaccines, future investigations monitoring the new-onset hypersomnia findings in vulnerable individuals are urgently needed.\u201d<\/p>\n\n\n\n Hypersomnia is the inability to stay awake and alert during the daytime, even though the person may have had plenty of sleep during the night.<\/p>\n\n\n\n About 15.9 percent of people who received Moderna shots had vertigo, a sensation which makes the individual feel that they or their surrounding environment is moving or spinning. It typically lasted for a day.<\/p>\n\n\n\n Paresthesia\u2014a feeling of numbness or itching on the skin for no apparent reason\u2014was reported<\/a> in 14.5 percent of Moderna vaccine recipients, which went away after a day.<\/p>\n\n\n\n Among the people who received a Moderna jab, 2.7 percent reported diplopia, also known as double vision, which also lasted for about a day. \u201cSymptomatic people showed an increased risk to develop diplopia after the second dose, as if a reactivation of the immune response was necessary to trigger diplopia.\u201d<\/p>\n\n\n\n Meanwhile, about 6.4 percent of Pfizer vaccine recipients reported suffering from cognitive fog, with the condition usually reversing in a week.<\/p>\n\n\n\n \u201cBrain fog is a type of cognitive impairment that presents as a \u2018foggy brain state\u2019, including a lack of intellectual clarity, difficulty with concentration, mental fatigue and anxiety,\u201d the study said.<\/p>\n\n\n\n \u201cHypotheses including systemic inflammation crossing the blood\u2013brain barrier, neuroinflammation after viral infection leads and microglial activation are emerging as explanations of this phenomenon in COVID-19 patients. An alternative speculation is that symptomatic people may have a subclinical cognitive dysfunction before vaccination, and that vaccination is a trigger.\u201d<\/p>\n\n\n\n The study found that females faced an \u201cincreased risk of developing neurological complications\u201d following COVID-19 vaccination. \u201cOur findings are in line with those of a recent study that revealed that several factors, including the female sex, were associated with greater odds of adverse effects,\u201d it said.<\/p>\n\n\n\n The researchers suggested that greater female susceptibility to the vaccines\u2019 neurological complications may be due to \u201cgenetic and hormonal factors.\u201d<\/p>\n\n\n\n Females have two X chromosomes while males have one X chromosome and one Y chromosome. As the X chromosome \u201ccontains the most prominent immune-related genes in the human genome,\u201d it can also cause \u201cstronger inflammatory immune responses,\u201d the study said.<\/p>\n\n\n\n Moreover, a primary female sex steroid called estradiol triggers a specific immunity process to produce \u201cantibodies against infections.\u201d<\/p>\n\n\n\n The study also raised concerns about comorbidities. In medical parlance, comorbidity describes the existence of more than one disease or condition in a body at the same time, which may or may not interact with one another.<\/p>\n\n\n\n \u201cThe evidence that immune system dysfunctions (allergies\/immunodeficiency disorders) are frequently reported in our symptomatic group is more than a chance occurrence,\u201d researchers said.<\/p>\n\n\n\n Comorbidities were present in 47.6 percent of the AstraZeneca vaccine recipients, 38.8 percent of those who took Moderna jabs, and 41.5 percent of individuals who received Pfizer shots, the study said.<\/p>\n\n\n\n In the AstraZeneca group, both allergies and non-neurological diseases were reported. \u201cA history of antitumoral and anticoagulant drugs was more frequent in this population,\u201d the study said.<\/p>\n\n\n\n Among Moderna and Pfizer recipients, allergies were \u201cmore frequently\u201d observed. While some people who took Moderna had a prior history of neurological diseases and transfusions as well as previous COVID-19 infection, those who received Pfizer vaccines had a history of immunodeficiency disorders.<\/p>\n\n\n\n Even though the study detailed neurological complications arising from COVID-19 vaccination, it admitted to certain limitations.<\/p>\n\n\n\n \u201cFirstly, our results should be interpreted with caution because of a possible overestimation of neurological events resulting from the self-reported symptoms,\u201d it said.<\/p>\n\n\n\n \u201cSecondly, we evaluated the risks associated with the first and second doses of the vaccine; however, the data concerning the second dose were limited, thus representing a potential bias in the study.\u201d<\/p>\n\n\n\n While admitting its limitations, the study concluded that \u201cclinicians should be aware that several neurological complications may commonly occur after COVID-19 vaccines.\u201d<\/p>\n\n\n\n \u201cCaution should be used when administering COVID-19 vaccines to vulnerable people, such as to those who suffer from allergies,\u201d the study stated. \u201cWe strongly believe that our findings are relevant for public health regarding the safety of vaccines in a large cohort.\u201d<\/p>\n\n\n\n The Epoch Times reached out to Moderna, Pfizer, and AstraZeneca for comment.<\/p>\n\n\n\n Cardiologist Dr. Peter McCullough wrote about the study<\/a> discussing neurological effects following COVID shots in an article on Substack.<\/p>\n\n\n\n \u201cA shocking 31.2 percent of respondents to this large dataset sustained neurologic injury after two injections with verified data in health registries,\u201d he wrote. \u201cMost of the risk estimates indicate the safety profile is unacceptable. It is alarming that all neurological societies to date still recommend COVID-19 vaccines and none have issued safety warnings on the products.\u201d<\/p>\n\n\n\n Dr. McCullough explained that an excess risk of 20 percent or greater is considered “clinically important.”<\/p>\n\n\n\n Multiple other studies have found evidence of COVID-19 vaccines being linked to neurological complications. Back in October 2021, a study<\/a> published in the Neurological Sciences journal stated that the \u201cmost devastating neurological post-vaccination complication is cerebral venous sinus thrombosis (CVST).\u201d<\/p>\n\n\n\n CVST occurs when a blood clot develops in the venous sinuses of the brain. This blocks the blood from draining out of the brain, eventually resulting in the blood leaking into brain tissues and forming a hemorrhage, according to Johns Hopkins Medicine.<\/p>\n\n\n\n The study found that CVST was \u201cfrequently reported in females of childbearing age,\u201d generally among those who took an adenovector vaccine. Individuals who received mRNA vaccination were reported to have Bell\u2019s palsy, in which facial muscles weaken or enter into paralysis.<\/p>\n\n\n\n A November 2022 study in Current Neurology and Neuroscience Reports<\/a> made similar findings, stating that there is \u201ca greater than expected occurrence of severe neurological adverse events.”<\/p>\n\n\n\nAstraZeneca Risks<\/h2>\n\n\n\n
Moderna and Pfizer Risks<\/h2>\n\n\n\n
Females Highly Affected<\/h2>\n\n\n\n
Additional Neurological Findings<\/h2>\n\n\n\n